|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
JO3701B1
(ar)
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
|
AR102198A1
(es)
|
2014-10-09 |
2017-02-08 |
Regeneron Pharma |
Proceso para reducir partículas subvisibles en una formulación farmacéutica
|
|
TWI797060B
(zh)
|
2015-08-04 |
2023-04-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
CN106928326B
(zh)
*
|
2015-12-31 |
2019-12-24 |
中国科学院微生物研究所 |
一种基于二聚化的受体结合区亚单位的冠状病毒疫苗
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
CN107298712B
(zh)
*
|
2016-04-14 |
2020-04-07 |
中国疾病预防控制中心病毒病预防控制所 |
全人源化抗中东呼吸综合征冠状病毒中和抗体
|
|
TW201815821A
(zh)
*
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
|
KR20230041834A
(ko)
|
2016-08-16 |
2023-03-24 |
리제너론 파아마슈티컬스, 인크. |
혼합물로부터 개별 항체들을 정량하는 방법
|
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
AU2017350807B2
(en)
|
2016-10-25 |
2022-07-07 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for chromatography data analysis
|
|
KR20180058206A
(ko)
*
|
2016-11-23 |
2018-05-31 |
에스케이케미칼 주식회사 |
중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
|
|
KR102777514B1
(ko)
|
2017-01-19 |
2025-03-06 |
옴니에이비 오퍼레이션스, 인코포레이티드 |
다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
|
|
CA3061236A1
(en)
|
2017-05-22 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Therapeutic compounds and compositions, and methods of use thereof
|
|
KR102782655B1
(ko)
|
2017-07-06 |
2025-03-14 |
리제너론 파마슈티칼스 인코포레이티드 |
당단백질을 만들기 위한 세포 배양 과정
|
|
KR101895228B1
(ko)
|
2017-08-23 |
2018-10-30 |
대한민국 |
중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도
|
|
JP7301043B2
(ja)
|
2017-09-19 |
2023-06-30 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
粒子の形成を低減する方法及びそれにより形成される組成物
|
|
WO2019067671A1
(en)
*
|
2017-09-27 |
2019-04-04 |
David Weiner |
DNA ANTIBODY CONSTRUCTS FOR USE IN CORONAVIRUS RESPIRATORY SYNDROME OF THE MIDDLE EAST
|
|
KR102017217B1
(ko)
*
|
2017-10-19 |
2019-09-02 |
주식회사 엔케이맥스 |
중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
|
|
EP3727629A1
(en)
|
2017-12-22 |
2020-10-28 |
Regeneron Pharmaceuticals, Inc. |
System and method for characterizing drug product impurities
|
|
CA3085177A1
(en)
|
2018-01-31 |
2019-08-08 |
Regeneron Pharamaceuticals, Inc. |
System and method for characterizing size and charge variant drug product impurities
|
|
WO2019151632A1
(ko)
*
|
2018-01-31 |
2019-08-08 |
(주)셀트리온 |
중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자
|
|
KR20190093107A
(ko)
*
|
2018-01-31 |
2019-08-08 |
(주)셀트리온 |
중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자
|
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
KR20200127979A
(ko)
|
2018-02-28 |
2020-11-11 |
리제너론 파마슈티칼스 인코포레이티드 |
바이러스 오염물질을 확인하기 위한 시스템 및 방법
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
KR102503356B1
(ko)
|
2018-03-19 |
2023-02-24 |
리제너론 파마슈티칼스 인코포레이티드 |
마이크로칩 모세관 전기영동 분석 및 시약
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
US11696948B2
(en)
|
2018-06-12 |
2023-07-11 |
Kbio Holdings Limited |
Vaccines formed by virus and antigen conjugation
|
|
US11690907B2
(en)
|
2018-06-12 |
2023-07-04 |
Kbio Holdings Limited |
Vaccines formed by virus and antigen conjugation
|
|
CN110616198B
(zh)
*
|
2018-06-19 |
2021-02-19 |
清华大学 |
一种基于黑猩猩腺病毒68型和MERS-CoV全长膜蛋白的新型冠状病毒疫苗
|
|
TWI853823B
(zh)
|
2018-07-02 |
2024-09-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
|
KR102682192B1
(ko)
*
|
2018-08-17 |
2024-07-04 |
한림대학교 산학협력단 |
메르스 코로나바이러스 s 단백질에 대한 단클론 항체 및 그 용도
|
|
KR20210052389A
(ko)
|
2018-08-27 |
2021-05-10 |
리제너론 파마슈티칼스 인코포레이티드 |
다운스트림 정제에서의 라만 분광법의 사용
|
|
CA3100038A1
(en)
|
2018-08-30 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
|
RU2709659C1
(ru)
*
|
2018-09-06 |
2019-12-19 |
федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
Иммунобиологическое средство и способ его использования для индукции специфического иммунитета к вирусу ближневосточного респираторного синдрома (варианты)
|
|
KR102007161B1
(ko)
*
|
2018-11-07 |
2019-08-07 |
대한민국 |
메르스 코로나 바이러스 스파이크 s1 단백질에 특이적으로 결합하는 단클론 항체
|
|
SG11202104237YA
(en)
|
2019-01-16 |
2021-05-28 |
Regeneron Pharma |
Methods for identifying free thiols in proteins
|
|
CN113874394B
(zh)
*
|
2019-02-20 |
2024-01-19 |
和铂抗体有限公司 |
抗体
|
|
US11364276B2
(en)
|
2019-03-26 |
2022-06-21 |
National Guard Health Affairs |
Antiviral peptides for treatment of the middle east respiratory syndrome
|
|
BR112021019512A2
(pt)
*
|
2019-04-03 |
2022-02-15 |
Regeneron Pharma |
Métodos para inserir uma sequência de codificação de proteína de ligação ao antígeno e para tratar ou efetuar a profilaxia de uma doença em um animal, animal, célula, genoma, ácido nucleico doador exógeno, gene de porto seguro, e, agente de nuclease ou um ou mais ácidos nucleicos
|
|
KR102213745B1
(ko)
*
|
2019-04-16 |
2021-02-09 |
주식회사 바이오앱 |
돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법
|
|
CA3135004A1
(en)
|
2019-05-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
WO2021060837A1
(en)
*
|
2019-09-23 |
2021-04-01 |
Seoul National University R&Db Foundation |
Anti-mers-cov antibody and use thereof
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
MY207613A
(en)
|
2019-11-25 |
2025-03-06 |
Regeneron Pharma |
Sustained release formulations using non-aqueous emulsions
|
|
CA3165060C
(en)
|
2020-01-21 |
2023-06-20 |
Yiming Zhao |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
AU2021219671A1
(en)
|
2020-02-10 |
2022-07-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-Tmprss2 Antibodies and Antigen-Binding Fragments
|
|
CN111592602B
(zh)
*
|
2020-02-10 |
2021-03-02 |
中国科学院微生物研究所 |
一种β冠状病毒抗原、其制备方法和应用
|
|
HUE062777T2
(hu)
|
2020-02-26 |
2023-12-28 |
Vir Biotechnology Inc |
SARS-CoV-2 elleni antitestek
|
|
CN113321713B
(zh)
*
|
2020-02-28 |
2022-11-01 |
深圳市亚辉龙生物科技股份有限公司 |
SARS-CoV-2的重组RBD蛋白及其制备方法
|
|
MX2022011142A
(es)
*
|
2020-03-09 |
2022-12-13 |
Abcellera Biologics Inc |
Anticuerpos anti-coronavirus y metodos de uso.
|
|
WO2021183780A1
(en)
*
|
2020-03-11 |
2021-09-16 |
Ibio, Inc. |
Lichenase-covid-19 based vaccine
|
|
PH12022552298A1
(en)
*
|
2020-03-12 |
2023-12-11 |
Cullis Hill Sydney David |
Treatment for coronavirus infection and associated cytokine toxicity
|
|
US11365239B2
(en)
*
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
|
WO2021207948A1
(en)
*
|
2020-04-14 |
2021-10-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-sars-cov-2 antibodies and uses thereof
|
|
EP4045533B1
(en)
|
2020-03-26 |
2023-11-15 |
Vanderbilt University |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
|
|
EP4125839A4
(en)
*
|
2020-04-01 |
2024-04-24 |
Thiogenesis Therapeutics, Inc. |
CYSTEAMINE PRECURSORS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS
|
|
WO2021201679A1
(en)
|
2020-04-01 |
2021-10-07 |
Kiadis Pharma Intellectual Property B.V. |
Compositions and methods targeting coronaviruses
|
|
CR20220552A
(es)
|
2020-04-02 |
2023-01-17 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
|
|
WO2021216876A2
(en)
*
|
2020-04-24 |
2021-10-28 |
The Board Of Regents Of The University Of Texas System |
Antibodies to coronavirus spike protein and methods of use thereof
|
|
EP4144353A4
(en)
*
|
2020-04-30 |
2024-08-28 |
FUJIFILM Toyama Chemical Co., Ltd. |
THERAPEUTIC AGENT AGAINST CORONAVIRUS INFECTION FORMED BY COMBINATION OF A PYRAZINE DERIVATIVE AND ANOTHER THERAPEUTIC DRUG AGAINST CORONAVIRUS INFECTION
|
|
GB202007532D0
(en)
*
|
2020-05-20 |
2020-07-01 |
Alchemab Therapeutics Ltd |
Polypeptides
|
|
WO2021238910A1
(en)
*
|
2020-05-25 |
2021-12-02 |
Guo Bingshi |
Anti-coronavirus spike protein antibodies and uses thereof
|
|
IL298194A
(en)
|
2020-05-26 |
2023-01-01 |
Regeneron Pharma |
Antibodies against sars-cov2-spike glycoprotein and antigen-binding fragments
|
|
CN111606981B
(zh)
*
|
2020-05-27 |
2022-02-08 |
中国医学科学院基础医学研究所 |
Sars-cov冠状病毒s1蛋白多肽及其应用
|
|
EP4161960A1
(en)
|
2020-06-03 |
2023-04-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
|
|
US20230227539A1
(en)
*
|
2020-06-16 |
2023-07-20 |
Hifibio (Hk) Limited |
Methods and compositions related to neutralizing antibodies against human coronavirus
|
|
US20240117010A1
(en)
*
|
2020-06-23 |
2024-04-11 |
Navigo Proteins Gmbh |
Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (sars-cov-2)
|
|
WO2022019711A1
(ko)
*
|
2020-07-24 |
2022-01-27 |
(주)셀트리온 |
코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자
|
|
WO2022026807A2
(en)
*
|
2020-07-30 |
2022-02-03 |
Albert Einstein College Of Medicine |
Antibodies targeting sars-cov-2 and uses thereof
|
|
JP2023537470A
(ja)
|
2020-08-03 |
2023-09-01 |
ヤンセン バイオテツク，インコーポレーテツド |
ウイルス治療における多方向バイオ輸送のための材料及び方法
|
|
JP2023536935A
(ja)
*
|
2020-08-07 |
2023-08-30 |
ノヴェルジェン カンパニー リミテッド |
コロナウイルスに対する抗ウイルス用組成物
|
|
JP2023542820A
(ja)
|
2020-08-31 |
2023-10-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
細胞培養成績を改善し、アスパラギン配列バリアントを軽減するためのアスパラギン供給戦略
|
|
WO2022054068A1
(en)
*
|
2020-09-14 |
2022-03-17 |
Ramot At Tel-Aviv University Ltd. |
Antibodies for the prevention, treatment and detection of coronavirus infection
|
|
US20250188154A1
(en)
*
|
2020-09-15 |
2025-06-12 |
Duke University |
Coronavirus antibodies and uses thereof
|
|
WO2022067020A1
(en)
*
|
2020-09-24 |
2022-03-31 |
The Broad Institute, Inc. |
Cell-free antibody engineering platform and neutralizing antibodies for sars-cov-2
|
|
CN112379087B
(zh)
*
|
2020-10-21 |
2022-02-11 |
中国医学科学院医学生物学研究所 |
一种应用于新型冠状病毒灭活疫苗的裂解液及抗原解离的方法
|
|
US12239687B2
(en)
|
2020-11-25 |
2025-03-04 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
EP4262757A1
(en)
|
2020-12-17 |
2023-10-25 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
|
CN114716541B
(zh)
*
|
2021-01-05 |
2023-07-21 |
中国科学院分子细胞科学卓越创新中心 |
抗冠状病毒的全人广谱中和抗体76e1及其应用
|
|
US11834493B2
(en)
|
2021-01-05 |
2023-12-05 |
Immunome, Inc. |
Antibody cocktail against SARS-CoV-2 spike protein
|
|
WO2022159432A1
(en)
|
2021-01-20 |
2022-07-28 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving protein titer in cell culture
|
|
AU2022210469A1
(en)
*
|
2021-01-22 |
2023-07-13 |
The Government Of The United States, As Represented By The Secretary Of The Army |
Monoclonal antibodies against corovaviruses and uses thereof
|
|
WO2022170126A2
(en)
*
|
2021-02-05 |
2022-08-11 |
Adagio Therapeutics, Inc. |
Compounds specific to coronavirus s protein and uses thereof
|
|
WO2022182662A1
(en)
|
2021-02-23 |
2022-09-01 |
10X Genomics, Inc. |
Compositions and methods for mapping antigen-binding molecule affinity to antigen regions of interest
|
|
EP4301784A4
(en)
*
|
2021-03-02 |
2025-01-01 |
NovaRock Biotherapeutics, Ltd. |
Antibodies against claudin-6 and uses thereof
|
|
AU2022230987A1
(en)
|
2021-03-03 |
2023-08-31 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for quantifying and modifying protein viscosity
|
|
WO2022187626A1
(en)
|
2021-03-05 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
|
|
WO2022197664A1
(en)
*
|
2021-03-15 |
2022-09-22 |
Emory University |
Sars-cov-2 antibodies and fragments, therapeutic uses, diagnostic uses, and compositions related thereto
|
|
US20240182551A1
(en)
*
|
2021-04-02 |
2024-06-06 |
The Scripps Research Institute |
Cross-reactive monoclonal antibodies against coronaviruses
|
|
WO2022241200A1
(en)
*
|
2021-05-14 |
2022-11-17 |
Vanderbilt University |
Cross-reactive coronavirus antibodies
|
|
AU2022286340A1
(en)
|
2021-06-01 |
2024-01-04 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
KR20240046322A9
(ko)
|
2021-07-14 |
2025-10-01 |
리제너론 파아마슈티컬스, 인크. |
항-sars-cov-2-스파이크 당단백질 항체 및 항원-결합 단편
|
|
KR20240046926A
(ko)
*
|
2021-07-23 |
2024-04-11 |
더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 |
Sars-cov-2, 그 변이체 및 관련 코로나바이러스를 강력하고 광범위하게 중화하는 단일클론항체의 특성 분석 및 사용 방법
|
|
AR127006A1
(es)
|
2021-09-08 |
2023-12-06 |
Regeneron Pharma |
UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
|
|
JP2024531800A
(ja)
|
2021-09-20 |
2024-08-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗体の不均一性を制御する方法
|
|
CN116178530A
(zh)
*
|
2021-09-26 |
2023-05-30 |
上海君实生物医药科技股份有限公司 |
抗体在治疗SARS-CoV-2感染的用途
|
|
EP4413364A2
(en)
|
2021-10-07 |
2024-08-14 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods of ph modeling and control
|
|
US20230110811A1
(en)
|
2021-10-07 |
2023-04-13 |
Regeneron Pharmaceuticals, Inc. |
pH METER CALIBRATION AND CORRECTION
|
|
WO2023064841A1
(en)
*
|
2021-10-13 |
2023-04-20 |
The Wistar Institute Of Anatomy And Biology |
Antibodies for use against sars-cov-2
|
|
AU2022376179A1
(en)
|
2021-10-26 |
2024-05-16 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
|
|
TW202342510A
(zh)
|
2022-02-18 |
2023-11-01 |
英商Ｒｑ生物科技有限公司 |
抗體
|
|
WO2023178182A1
(en)
|
2022-03-16 |
2023-09-21 |
10X Genomics, Inc. |
Compositions and methods for detection and treatment of coronavirus infection
|
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
TW202445135A
(zh)
|
2023-01-25 |
2024-11-16 |
美商再生元醫藥公司 |
液態蛋白質組成物穩定性之建模方法
|
|
TW202445138A
(zh)
|
2023-02-01 |
2024-11-16 |
美商再生元醫藥公司 |
用於生物巨分子分析之具質譜法的不對稱流場流分離
|
|
TW202446462A
(zh)
|
2023-02-22 |
2024-12-01 |
美商再生元醫藥公司 |
系統適用性參數及管柱老化
|
|
AU2024265540A1
(en)
|
2023-05-01 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Multidose antibody drug products using phenol or benzyl alcohol
|
|
TW202532098A
(zh)
|
2023-09-29 |
2025-08-16 |
美商再生元醫藥公司 |
使用控制成核之冷凍乾燥
|
|
WO2025085594A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
WO2025096932A1
(en)
|
2023-11-02 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
CN119264262B
(zh)
*
|
2024-09-19 |
2025-09-02 |
中山大学 |
一种双特异性抗体及其应用
|